Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 152, Issue 1, Pages 17-26Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ajcp/aqz012
Keywords
ASCO; CAP HER2 guidelines; Breast cancer; HER2 FISH; HER2 IHC
Categories
Funding
- Ohio State University College of Medicine Roessler Research Scholarship
Ask authors/readers for more resources
Objectives The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline focused update revises the HER2 scoring criteria. We evaluated the impact on HER2 rates in breast carcinoma diagnosed at our center. Methods In a retrospective series of breast core biopsies with invasive carcinoma diagnosed between 2014 and 2017 (n = 1,350), HER2 status was classified according to 2013 and 2018 ASCO/CAP guidelines and changes in HER2 status identified. Results The 2018 guidelines reclassified the HER2 status of 6% of patients. Most changed from HER2 equivocal status (equivocal by immunohistochemistry and fluorescence in situ hybridization under the 2013 guidelines) to HER2-negative status (2018 guidelines). The HER2-positive rate decreased by 0.4%. Conclusions The 2018 guidelines decrease the rate of HER2 equivocal and positive breast cancer and reduce repeat HER2 testing on excision specimens. Approximately 0.4% of patients will become newly ineligible for anti-HER2 therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available